REGENXBIO: Funding, Investors & Team (Sep 2026)
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
REGENXBIO has raised $290M across 2 funding rounds on record, the most recent an undisclosed round of $150M announced in May 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
REGENXBIO Company Profile and Key Stats
Latest funding round on record: May 2025.
REGENXBIO Funding Rounds
REGENXBIO raised $140M in an undisclosed round announced in Mar 2024.
1.2 years later, an undisclosed round of $150M was announced in May 2025.
REGENXBIO Founders and Leadership Team
Contact details for the REGENXBIO team: 1 of 2 have an email address on file.
Start 14-day free trial →REGENXBIO Funding Compared to Other Biotechnology Startups
REGENXBIO's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like REGENXBIO in Biotechnology and Rockville
Companies Similar to REGENXBIO
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
REGENXBIO Funding FAQs
What does REGENXBIO do?
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
How much funding has REGENXBIO raised?
REGENXBIO has raised $290M across 2 rounds on record. The most recent is an undisclosed round of $150M announced in May 2025.
When did REGENXBIO last raise funding?
REGENXBIO's most recent funding round on record is an undisclosed round of $150M, announced in May 2025.
Who founded REGENXBIO?
FundedIQ lists Kenneth Mills (Founder), Kenneth T Mills (Founder) at REGENXBIO.
Where is REGENXBIO headquartered?
REGENXBIO is based in Rockville, Maryland, United States.
How many employees does REGENXBIO have?
REGENXBIO is in the 251-500 employee band.
How does REGENXBIO's funding compare to other Biotechnology startups?
REGENXBIO's latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's REGENXBIO Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for REGENXBIO is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.